<div class="welcome-screen" id="welcomeScreen">
    <div class="welcome-banner">
        <h1 id="welcome-title">Welcome to page on antidepressants and antipsychotics!</h1>
        <p id="welcome-description">Explore the following topics to enhance your knowledge.</p>
    </div>
    
    <div class="explanation-card">
        <h1>Introduction to Depression, Psychosis, and Their Pharmacological Treatment</h1>
        <p><strong>Depression</strong> and <strong>psychosis</strong> are debilitating psychiatric disorders with distinct yet sometimes overlapping neurobiological underpinnings. <strong>Depression</strong> is characterized by persistent sadness, anhedonia, cognitive impairment, and somatic symptoms, while <strong>psychosis</strong> involves hallucinations, delusions, and disorganized thinking. Both conditions arise from dysregulation in <strong>monoaminergic (dopamine, serotonin, norepinephrine)</strong> and <strong>glutamatergic pathways</strong>.</p>
        
        <h2>Neuroanatomy and Neurophysiology</h2>
        <p>The <strong>limbic system</strong> (amygdala, hippocampus, prefrontal cortex) modulates mood and is hypoactive in depression. The <strong>mesolimbic and mesocortical dopamine pathways</strong> are implicated in psychosis, with hyperactivity in the mesolimbic pathway contributing to positive symptoms (e.g., hallucinations) and hypoactivity in the mesocortical pathway leading to negative symptoms (e.g., blunted affect).</p>
        
        <h2>Historical Context</h2>
        <p>The discovery of <strong>imipramine</strong> (the first tricyclic antidepressant, TCA) in the 1950s revolutionized depression treatment, while <strong>chlorpromazine</strong> (the first antipsychotic) transformed psychosis management by blocking dopamine D2 receptors. The <strong>monoamine hypothesis</strong> of depression posits that deficits in serotonin (5-HT), norepinephrine (NE), and dopamine (DA) underlie depressive symptoms, whereas the <strong>dopamine hypothesis</strong> of psychosis suggests excessive dopaminergic transmission in subcortical regions.</p>
    </div>

    <div class="question-card">
        <h1>Question 1</h1>
        <p>Which pathway is primarily implicated in the positive symptoms of psychosis?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Mesolimbic dopamine pathway</li>
            <li data-answer="wrong">Mesocortical dopamine pathway</li>
            <li data-answer="wrong">Nigrostriatal dopamine pathway</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 2</h1>
        <p>Which neurotransmitter is LEAST associated with the monoamine hypothesis of depression?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Serotonin</li>
            <li data-answer="wrong">Norepinephrine</li>
            <li data-answer="correct">Glutamate</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Depression: Treatment Schedule</h1>
        <p>Treatment of depression follows a <strong>stepwise approach</strong>:</p>
        <ol>
            <li><strong>First-line:</strong> Selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine) or serotonin-norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine).</li>
            <li><strong>Second-line:</strong> Atypical antidepressants (e.g., bupropion, mirtazapine) or augmentation with lithium/thyroid hormone.</li>
            <li><strong>Third-line:</strong> Tricyclic antidepressants (TCAs, e.g., amitriptyline) or monoamine oxidase inhibitors (MAOIs, e.g., phenelzine).</li>
            <li><strong>Adjunctive therapies:</strong> Cognitive-behavioral therapy (CBT), electroconvulsive therapy (ECT) for refractory cases.</li>
        </ol>
        
        <h2>Key Considerations</h2>
        <p><strong>Onset of action:</strong> Antidepressants typically require <strong>2–6 weeks</strong> for clinical effect due to downstream neuroplasticity changes (e.g., BDNF upregulation). <strong>SSRIs</strong> are preferred due to their favorable side-effect profile, whereas <strong>TCAs</strong> are reserved for treatment-resistant cases due to anticholinergic/cardiotoxic risks.</p>
        
        <div class="mnemonic">
            <p><strong>Mnemonic: "START LOW, GO SLOW"</strong> – Antidepressants should be initiated at low doses to minimize side effects (e.g., SSRI-induced GI distress) and titrated gradually.</p>
        </div>
    </div>

    <div class="question-card">
        <h1>Question 3</h1>
        <p>Which class of antidepressants is contraindicated in patients with recent myocardial infarction?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">SSRIs</li>
            <li data-answer="correct">TCAs</li>
            <li data-answer="wrong">SNRIs</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 4</h1>
        <p>What is the typical latency period for clinical response to SSRIs?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">1–3 days</li>
            <li data-answer="correct">2–6 weeks</li>
            <li data-answer="wrong">6–12 months</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Psychosis: Treatment Schedule</h1>
        <p>Antipsychotics are classified as <strong>first-generation (FGAs, typical)</strong> or <strong>second-generation (SGAs, atypical)</strong>. FGAs (e.g., haloperidol) primarily block D2 receptors, while SGAs (e.g., risperidone) target both D2 and 5-HT2A receptors.</p>
        
        <h2>Acute Phase</h2>
        <p><strong>SGAs</strong> (e.g., olanzapine, quetiapine) are first-line due to lower extrapyramidal side effect (EPS) risk. <strong>FGAs</strong> may be used for rapid sedation (e.g., haloperidol + lorazepam IM).</p>
        
        <h2>Maintenance Phase</h2>
        <p>Long-acting injectables (LAIs, e.g., paliperidone) improve adherence. Clozapine is reserved for <strong>treatment-resistant schizophrenia</strong> (failure of ≥2 antipsychotics).</p>
        
        <div class="mnemonic">
            <p><strong>Mnemonic: "CLOZAPINE is the KING of antipsychotics"</strong> – Clozapine is the most effective but requires weekly ANC monitoring due to agranulocytosis risk.</p>
        </div>
    </div>

    <div class="question-card">
        <h1>Question 5</h1>
        <p>Which antipsychotic requires mandatory hematologic monitoring?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Clozapine</li>
            <li data-answer="wrong">Risperidone</li>
            <li data-answer="wrong">Aripiprazole</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 6</h1>
        <p>Which receptor profile distinguishes SGAs from FGAs?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">D2 + muscarinic</li>
            <li data-answer="correct">D2 + 5-HT2A</li>
            <li data-answer="wrong">D2 + α1</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Antidepressants: Pharmacodynamics, Pharmacokinetics, and Adverse Effects</h1>
        <h2>SSRIs (e.g., Fluoxetine, Sertraline)</h2>
        <p><strong>Mechanism:</strong> Inhibit SERT (serotonin transporter), increasing synaptic 5-HT. <strong>Side effects:</strong> GI distress, sexual dysfunction, SIADH, QT prolongation (citalopram). <strong>PK:</strong> Hepatic metabolism (CYP2D6/CYP3A4); fluoxetine has a long half-life (active metabolite norfluoxetine).</p>
        
        <h2>SNRIs (e.g., Venlafaxine, Duloxetine)</h2>
        <p><strong>Mechanism:</strong> Inhibit SERT + NET (norepinephrine transporter). <strong>Side effects:</strong> Hypertension (dose-dependent NE effect), sweating, nausea. <strong>PK:</strong> Venlafaxine is a CYP2D6 substrate.</p>
        
        <h2>TCAs (e.g., Amitriptyline)</h2>
        <p><strong>Mechanism:</strong> Inhibit SERT + NET + anticholinergic/antihistaminergic effects. <strong>Side effects:</strong> Orthostatic hypotension, arrhythmias (Na+ channel blockade), dry mouth. <strong>PK:</strong> Highly protein-bound, CYP2D6 metabolism.</p>
        
        <div class="mnemonic">
            <p><strong>Mnemonic: "TCAs are DIRTY drugs"</strong> – They have Diverse Interactions and Risky Toxicities (e.g., overdose lethality).</p>
        </div>
    </div>

    <div class="question-card">
        <h1>Question 7</h1>
        <p>Which antidepressant is most likely to cause hypertension at high doses?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Venlafaxine</li>
            <li data-answer="wrong">Sertraline</li>
            <li data-answer="wrong">Mirtazapine</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 8</h1>
        <p>Which enzyme primarily metabolizes venlafaxine?</p>
        <ul class="options" id="options">
            <li data-answer="correct">CYP2D6</li>
            <li data-answer="wrong">CYP3A4</li>
            <li data-answer="wrong">CYP1A2</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Antipsychotics: Pharmacodynamics, Pharmacokinetics, and Adverse Effects</h1>
        <h2>FGAs (e.g., Haloperidol)</h2>
        <p><strong>Mechanism:</strong> Potent D2 antagonism. <strong>Side effects:</strong> EPS (parkinsonism, dystonia, akathisia), tardive dyskinesia, hyperprolactinemia. <strong>PK:</strong> CYP3A4 metabolism.</p>
        
        <h2>SGAs (e.g., Risperidone, Olanzapine)</h2>
        <p><strong>Mechanism:</strong> D2 + 5-HT2A antagonism. <strong>Side effects:</strong> Metabolic syndrome (weight gain, diabetes), sedation (H1 blockade), orthostasis (α1 blockade). <strong>PK:</strong> Olanzapine is metabolized by CYP1A2 (smoking ↓ levels).</p>
        
        <div class="mnemonic">
            <p><strong>Mnemonic: "OLANZAPINE is HEAVY"</strong> – High risk of weight gain, sedation, and metabolic effects.</p>
        </div>
    </div>

    <div class="question-card">
        <h1>Question 9</h1>
        <p>Which antipsychotic is most associated with metabolic syndrome?</p>
        <ul class="options" id="options">
            <li data-answer="correct">Olanzapine</li>
            <li data-answer="wrong">Haloperidol</li>
            <li data-answer="wrong">Aripiprazole</li>
        </ul>
    </div>

    <div class="question-card">
        <h1>Question 10</h1>
        <p>Which adverse effect is irreversible?</p>
        <ul class="options" id="options">
            <li data-answer="wrong">Akathisia</li>
            <li data-answer="correct">Tardive dyskinesia</li>
            <li data-answer="wrong">Orthostatic hypotension</li>
        </ul>
    </div>

    <div class="explanation-card">
        <h1>Off-Label and Non-Psychiatric Uses</h1>
        <h2>Antidepressants</h2>
        <p><strong>TCAs:</strong> Neuropathic pain (amitriptyline), migraine prophylaxis. <strong>SSRIs:</strong> Premenstrual dysphoric disorder (PMDD), OCD. <strong>Bupropion:</strong> Smoking cessation.</p>
        
        <h2>Antipsychotics</h2>
        <p><strong>Quetiapine:</strong> Insomnia (low-dose). <strong>Haloperidol:</strong> Delirium. <strong>Aripiprazole:</strong> Augmentation in MDD.</p>
    </div>

    <div class="placeholder" id="empty">Test</div>

</div>